John M H de Klerk
Overview
Explore the profile of John M H de Klerk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
698
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Sar E, Lavalaye J, Braat A, de Klerk J, Lam M, de Keizer B
Ned Tijdschr Geneeskd
. 2023 Jan;
167.
PMID: 36633055
PSMA PET/CT is a diagnostic technique for patients with prostate cancer. It makes use of a radioligand that specifically binds to 'prostate specific membrane antigen' (PSMA), expressed by the prostate...
2.
Borgonje P, Andrews L, Herder G, de Klerk J
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428657
Fibroblast activation protein (FAP) could be a promising target for tumor imaging and therapy, as it is expressed in >90% of epithelial cancers. A high level of FAP-expression might be...
3.
de Koster E, Noortman W, Mostert J, Booij J, Brouwer C, de Keizer B, et al.
Eur J Nucl Med Mol Imaging
. 2022 Feb;
49(7):2174-2188.
PMID: 35138444
Purpose: To evaluate whether quantitative [F]FDG-PET/CT assessment, including radiomic analysis of [F]FDG-positive thyroid nodules, improved the preoperative differentiation of indeterminate thyroid nodules of non-Hürthle cell and Hürthle cell cytology. Methods:...
4.
van Kalmthout L, van Melick H, Lavalaye J, Meijer R, Kooistra A, de Klerk J, et al.
J Urol
. 2019 Dec;
203(3):545.
PMID: 31794357
No abstract available.
5.
van Kalmthout L, van Melick H, Lavalaye J, Meijer R, Kooistra A, de Klerk J, et al.
J Urol
. 2019 Sep;
203(3):537-545.
PMID: 31487220
Purpose: Prospective validation of Ga prostate specific membrane antigen positron emission tomography/computerized tomography is lacking in initial staging of prostate cancer. In this study we evaluated the diagnostic accuracy of...
6.
Jansen B, Jansen R, Wondergem M, Srbljin S, de Klerk J, Lissenberg-Witte B, et al.
J Nucl Med
. 2019 Sep;
61(2):210-216.
PMID: 31481580
Biochemically recurrent prostate cancer (BCR) is the main indication to perform prostate-specific membrane antigen PET/CT. However, localizing BCR with prostate-specific membrane antigen PET/CT remains challenging in patients with low prostate-specific...
7.
Usmanij E, Senden P, Meiss L, de Klerk J
Eur Heart J Case Rep
. 2019 Apr;
2(2):yty069.
PMID: 31020146
Introduction: Subclavian artery stenosis occurs up to 4.6% in patients who are referred for a coronary artery bypass graft (CABG). Subclavian artery stenosis can compromise the blood flow in the...
8.
Bouman-Wammes E, de Klerk J, Bloemendal H, Van Dodewaard-de Jong J, Lange R, Ter Heine R, et al.
Clin Genitourin Cancer
. 2018 Dec;
17(2):e281-e292.
PMID: 30555024
In patients with metastatic castration-resistant prostate cancer, bone is the most common site for metastases. Because of their osteoblastic character, these lesions are very suitable for treatment with bone-seeking radiopharmaceuticals...
9.
Adams H, de Klerk J, Regelink J, Heggelman B, Dubois S, Kwee T
Nucl Med Mol Imaging
. 2017 Dec;
51(4):371-373.
PMID: 29242737
A 22-year-old woman was diagnosed with intermediate risk stage II Hodgkin lymphoma and treated with three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by involved-field radiation therapy. A...
10.
Kwee T, de Klerk J, Nix M, Heggelman B, Dubois S, Adams H
Semin Nucl Med
. 2017 Jun;
47(4):322-351.
PMID: 28583274
Positron emission tomography with the radiotracer F-fluoro-2-deoxy-d-glucose (FDG) plays an important role in the evaluation of bone pathology. However, FDG is not a cancer-specific agent, and knowledge of the differential...